Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population.
Kanai M, Kawaguchi T, Kotaka M, Manaka D, Hasegawa J, Takagane A, Munemoto Y, Kato T, Eto T, Touyama T, Matsui T, Shinozaki K, Matsumoto S, Mizushima T, Mori M, Sakamoto J, Ohtsu A, Yoshino T, Saji S, Matsuda F. Kanai M, et al. Among authors: sakamoto j. Cancer Med. 2023 Apr;12(7):7808-7814. doi: 10.1002/cam4.5541. Epub 2022 Dec 16. Cancer Med. 2023. PMID: 36524458 Free PMC article.
Differences in efficacy of biweekly irinotecan plus cisplatin versus irinotecan alone in second-line treatment of advanced gastric cancer with or without prior gastrectomy.
Nishikawa K, Koizumi W, Tsuburaya A, Suzuki M, Morita S, Fujitani K, Akamaru Y, Shimada K, Hosaka H, Nishimura K, Yoshikawa T, Tsujinaka T, Sakamoto J. Nishikawa K, et al. Among authors: sakamoto j. Int J Clin Oncol. 2024 Nov 25. doi: 10.1007/s10147-024-02661-6. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39585516
Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial).
Yamashita Y, Morimoto T, Muraoka N, Shioyama W, Chatani R, Shibata T, Nishimoto Y, Ogihara Y, Doi K, Oi M, Shiga T, Sueta D, Kim K, Tanabe Y, Koitabashi N, Takada T, Ikeda S, Nakagawa H, Tsukahara K, Shoji M, Sakamoto J, Hisatake S, Ogino Y, Fujita M, Nakanishi N, Dohke T, Hiramori S, Nawada R, Kaneda K, Ono K, Kimura T; ONCO PE Trial Investigators. Yamashita Y, et al. Among authors: sakamoto j. Circulation. 2024 Nov 18. doi: 10.1161/CIRCULATIONAHA.124.072758. Online ahead of print. Circulation. 2024. PMID: 39556015 Free article.
1,151 results